Tag: AbbVie

AbbVie is a pharmaceutical company that discovers, develops and markets both biopharmaceuticals and small molecule drugs. It originated in 2013 as a spin-off of Abbott Laboratories. On October 19, 2011, Abbott Laboratories announced its plan to separate into two publicly traded companies. The “new” Abbott Laboratories would specialize in diversified products including medical devices, diagnostic equipment and nutrition products, while AbbVie would operate as a research-based pharmaceutical manufacturer.

AbbVie and Allergan receive conditional approval from the European Commission

The European Commission approved AbbVie's merger with Allergan on the condition the companies sell off Allergan's late-stage IL-23 inhibitor brazikumab. That stipulation is far from a deal-breaker; Al...

Russian Ministry of Health Approved Upadacitinib

abbvie
The global research biopharmaceutical company AbbVie announces that the Ministry of Health of the Russian Federation has approved the RANVEC drug (upadacitinib) for oral administration once a day at a...

AbbVie and Scripps Research Announce Collaboration to Develop New Therapies

AbbVie and Scripps Research announced a collaboration to develop new therapies for a range of diseases, including in the therapeutic areas of oncology, immunology, neurology and fibrosis. "Based on o...

AbbVie Announced Collaboration with Scripps Research to Develop New Therapies

AbbVie, a research-based global biopharmaceutical company and Scripps Research, an international leader in non-profit biomedical research and drug discovery, announced a collaboration to develop new t...

Mission Therapeutics and AbbVie to Collaborate in AD and PD Study

alzheimer's disease
Mission Therapeutics, a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), and AbbVie, a global, research-driven biopharmaceutical company, annou...

AbbVie, NorthWest EHealth Partnered to Explore Associations Between Autoimmune Conditions

abbvie
AbbVie, a research-based global biopharmaceutical company, together with NorthWest EHealth, announces their partnership to explore the underlying associations between autoimmune conditions. The col...

Harpoon Therapeutics and AbbVie Announced Exclusive Transaction for HPN217

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of T cell engagers, and AbbVie Inc., a global biopharmaceutical company, announced an exclusive worldwide op...

Dragonfly Therapeutics and AbbVie Entered into Multi-Target Research Collaboration

abbvie office
Dragonfly Therapeutics, a biotechnology company developing novel immunotherapies that harness the innate immune system to treat disease, and AbbVie, a research-based global biopharmaceutical company, ...

AbbVie Announced Positive Data from RINVOQ™ Study

abbvie
AbbVie, a research-based global biopharmaceutical company, announced positive top-line data from the SELECT-PsA 2 Phase 3 study. In this study, both doses of RINVOQ™ (upadacitinib; 15 mg and 30 mg, on...

AbbVie Announced Strategic Collaboration with Cystic Fibrosis Foundation

abbvie
AbbVie, a research-based global biopharmaceutical company, and the Cystic Fibrosis Foundation announced a strategic collaboration in which AbbVie will develop a cystic fibrosis transmembrane conductan...

Allergan Shareholders Approved Proposed Acquisition of Allergan by AbbVie

Allergan plc announced that its shareholders have voted to approve the previously announced proposed acquisition of Allergan by AbbVie Inc. As described below, more than 99 percent of the votes cas...

FDA Granted Approval of AbbVie’s MAVYRET®

abbvie
AbbVie, a research-based global biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has granted approval of MAVYRET® (glecaprevir/pibrentasvir) to shorten the once-da...

NICE Recommended AbbVie’s Skyrizi for Plaque Psoriasis

AbbVie’s Skyrizi (risankizumab) has been awarded a positive recommendation from UK drug watchdog NICE, meaning that the IL-23 inhibitor will now be made available to eligible patients across England a...

FDA Approved AbbVie Janus Kinase Inhibitor

AbbVie, a research-based global biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved RINVOQ™ (upadacitinib), a 15 mg, once-daily oral Janus kinase (JAK) i...

EU Approved Two New Imbruvica Uses

European regulators have approved AbbVie and Janssen’s Imbruvica (ibrutinib) in two expanded uses that broaden the use of the blood cancer drug. Johnson & Johnson’s pharma unit said the Europea...

R-Pharm Starting Production of Abbvie’s Sevoran Analog

R-pharm
Russian drugmaker R-Pharm is expanding its line of generics of original drugs by starting production of an analog of Sevoran (sevoflurane), which is an anesthetic produced by the US biopharma company ...